Innovations in Oncology: Disease and Pipeline Highlights Webinar Series
In partnership, AMCP and HOPA (Hematology/Oncology Pharmacy Association) are producing a series of six live, CPE accredited half-hour webinars starting in September 2021. Each webinar will be recorded and converted into an enduring online activity.
Managed care professionals and hematology/oncology pharmacists actively work with providers to improve patient outcomes, stay current on innovative cancer treatments, and optimize the quality of life and longevity of patients with cancer. Each webinar session will provide an overview of the epidemiology, current cancer management strategy, and a summary of new treatments likely to be available for that specific cancer in the next 6-12 months.
This educational activity is supported by unrestricted educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.
Would your peers be interested in attending? Tell them to join you (virtually, of course)!
Schedule and Registration
Thursday, Sep. 2, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Lung Cancer
The emergence of novel targeted therapies and regimens for non-small cell lung cancer (NSCLC), including both those developed initially for NSCLC and those that were first approved for other solid organ tumors, has led to important changes in the treatment of both early-stage and metastatic disease in recent years. Additional promising therapies and novel treatment approaches are currently under investigation, such as treatments that target resistance to targeted therapies, and those that implement molecular and genetic testing to guide treatment selection. During this session, presenters will discuss recent evidence-based treatment innovations, recent changes to treatment guidelines, and explore emerging innovations that may impact NSCLC management in the future. Novel therapies in development including potential roles in treatment, and thresholds of evidence required for selecting treatments for individual patients will be discussed.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the incidence and current treatment landscape of non-small cell lung cancer (NSCLC).
2. Discuss recently approved novel treatment approaches for NSCLC and their pharmacology.
3. Recognize the mechanisms of action and potential impact of emerging treatment options on NSCLC treatment guidelines and recommendations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Amber Cipriani, PharmD, BCOP
Precision Medicine Pharmacy Coordinator, UNC Health Medical Center
Clinical Assistant Professor, UNC Eshelman School of Pharmacy
Chapel Hill, N.C.
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Lung Cancer
Amber Cipriani, PharmD, BCOP
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-035-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
Thursday, Sep. 9, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Breast Cancer
The emergence of novel targeted therapies and regimens for breast cancer has led to important changes in the treatment of both early-stage and metastatic disease in recent years. Additional promising therapies are currently in the pipeline with a variety of new pathways and treatment approaches under investigation. During this session, presenters will discuss new data, recent changes to treatment guidelines, and explore emerging innovations that may impact breast cancer management in the future. Novel therapies in development and evolving targets will be discussed, including potential roles in treatment.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the incidence of breast cancer and current treatment landscape for various subtypes.
2. Identify promising emerging treatment options for patients with breast cancer and their mechanisms of action.
3. Describe the potential impact of emerging treatment options on breast cancer treatment guidelines and recommendations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Kelly Gaertner, PharmD, BCOP, BCPS
Oncology Clinical Pharmacy Specialist
Allegheny Health Network Cancer Institute
Pittsburgh, Pa.
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Breast Cancer
Kelly Gaertner, PharmD, BCOP, BCPS
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-036-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
Thursday, Oct. 7, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Renal Cell Carcinoma
The number of pharmacologic treatment options for clear cell renal cancer, including both immunotherapies and novel targeted therapies, has recently expanded and is expected to continue to grow. These new options offer promise for improved outcomes but also complicate the selection of treatment regimens for patients, particularly for second- and third-line therapies. Additional promising therapies are currently in the pipeline, with a variety of new pathways and treatment approaches under investigation. During this session, presenters will provide an overview of recent developments in the pharmacologic treatment of renal cancer and explore emerging innovations. Potential roles in therapy, including patient factors to consider when individualizing treatment decisions, will be discussed.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the incidence of renal cancer and current treatment landscape for advanced or metastatic clear cell renal cancer.
2. Identify promising emerging treatment options for patients with for advanced or metastatic clear cell renal cancer and their mechanisms of action.
3. Describe the potential impact of emerging treatment options on for advanced or metastatic clear cell renal cancer treatment guidelines and recommendations, including sequencing considerations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Clinical Professor
UConn School of Pharmacy/UConn Health Carole & Ray Neag Comprehensive Cancer Center
Storrs Manfld, Conn.
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Renal Cell Carcinoma
Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-037-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
Thursday, Oct. 14, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Prostate Cancer
Novel approaches to the treatment of prostate cancer range from exploration of the use of androgen-deprivation therapy, radioligands approved for treatment of other conditions, and the use of immune checkpoint inhibitors in combination with other agents. These recent advances hold promise to improve outcomes for patients as careful attention to individualized patient factors can support selecting among available treatment approaches. During this session, presenters will provide an overview of novel treatment options for prostate cancer and discuss how emerging innovations may impact its management.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the incidence and current treatment landscape for prostate cancer.
2. Recognize the mechanisms of action for emerging treatment options for prostate cancer.
3. Explain the potential impact of emerging treatment options on prostate cancer guidelines and recommendations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Steven Ludlow, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist
H Lee Moffitt Cancer Center and Research Institute
Saint Petersburg, Fla.
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Prostate Cancer
Steven Ludlow, PharmD, BCOP, BCPS
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-057-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
Thursday, Nov. 4, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Acute Myeloid Leukemia
The treatment landscape for patients diagnosed with acute myeloid leukemia (AML) has undergone significant growth over the last five years with numerous practice-changing FDA approvals. These, predominantly oral, agents introduce new toxicity profiles, drug interactions, and financial implications to the AML treatment paradigm. Patient-centered targeted treatment design incorporating molecular aberrations, pharmacoeconomic considerations, and novel pathways is now considered the standard of care. Additional promising therapies are currently in the pipeline with a variety of new pathways and treatment approaches under investigation. During this session, presenters will discuss new data, recent changes to treatment guidelines, and explore emerging innovations and controversies that may impact acute myeloid leukemia management in the future. Novel therapies in development and evolving targets will be discussed, including potential roles in treatment.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the current treatment landscape for acute myeloid leukemia according to subtype.
2. Recognize the mechanisms of action for promising emerging treatment options for patients with acute myeloid leukemia.
3. Explain the potential impact of emerging treatment options on acute myeloid leukemia treatment guidelines and recommendations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Kayleigh R. Marx, PharmD, BCOP
Leukemia Clinical Pharmacy Specialist
University of Texas MD Anderson Cancer Center
Houston, Texas
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Acute Myeloid Leukemia
Kayleigh R. Marx, PharmD, BCOP
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-038-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
Thursday, Nov. 11, 2021
12-12:30pm ET — Innovations in Oncology: Focus on Multiple Myeloma
Recent advances in understanding the pathophysiology of multiple myeloma (MM) have led to the approval of novel drug classes and treatment options. Advances in treatment offer hope for patients but require careful selection among a range of agents with various mechanisms of action, toxicity profiles, and considerations for individualizing therapy. Additional promising therapies are currently in the pipeline with a variety of new pathways and treatment approaches under investigation. During this session, presenters will provide an overview of novel treatment options and discuss how emerging innovations may impact the management of MM.
Learning Objectives
At the completion of this knowledge-based activity, participants should be able to:
1. Describe the incidence and current treatment landscape for multiple myeloma.
2. Recognize the mechanisms of action for promising emerging treatment options for patients with multiple myeloma.
3. Explain the potential impact of emerging treatment options on multiple myeloma treatment guidelines and recommendations.
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Faculty
Houry Leblebjian, PharmD, BCOP
Clinical Pharmacy Practice Manager
Dana Farber Cancer Institute
Boston, Mass.
Moderator
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Coconut Creek, Fla.
Agenda
12:00-12:02pm — Welcome and Introductions
Laura R. Bobolts, PharmD, BCOP
12:02-12:25pm — Presentation: Innovations in Oncology: Focus on Multiple Myeloma
Houry Leblebjian, PharmD, BCOP
12:25-12:30pm — Audience Q&A
Laura R. Bobolts, PharmD, BCOP
Continuing Education Credit — Pharmacists
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Earning CPE Credit
To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions.
-
ACPE UAN #: 0233-9999-21-058-H01-P
-
Credit: 0.5 contact hours (0.05 CEU)
-
Activity Type: Knowledge-based
-
Activity Fee: There is no fee to participate in this activity.
